Journal of Ayurveda and Integrative Medicine (Jan 2022)
An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2
Abstract
Background: COVID-19 is the disease caused by SARS-CoV2, it was identified in Wuhan, China, in 2019. It then extended across the globe and was termed as a pandemic in 2020. Though research work on its vaccine and drugs are carried out across the globe, it is even necessary to look over it through alternative sciences. Objective: The objective of this study is to look over the disease through Ayurvedic perspective, analyse possible pathologies, select appropriate drugs and to study in-silico screening on these selected drugs. Materials & Methods: Available symptoms of COVID-19 were thoroughly studied and reviewed through Ayurveda classics, internet, preprints, etc. to understand the nature of the disease with the Ayurvedic perspective. The molecular Docking and Grid were generated through Pyrx Software with Autodock. The Lipinski Rule of Five data generated from Swiss ADME software and Target prediction of selected phytoconstituents were done by Swiss target prediction. Results: In Ayurveda, COVID-19 can be considered as Janapadaudhwans, Vata-Kaphaja Sannipatika Jwara, Aupasargika Vyadhi, and Dhatupaka Awastha. In the molecular docking study, the binding energy and inhibition of 6 Gingesulphonic acid from Zingiber officinalis (Sunthi) is greater than hydroxychloroquine and quinine. Most of the selected phytoconstituents follow the Lipinski rule of five. Target prediction of selected phytoconstituents was done on target of SARS-CoV-2, humoral immunity, and antiviral activity. Every selected phytoconstituents works on minimum one of the targets. Conclusion: Thus, from the above results obtained from reviewing Ayurveda classics and after the virtual screening of selected drugs we can conclude that Nagaradi Kashaya (Sunthi, Puskarmoola, Kantakari, Guduchi) may have appreciable results in combating SARS-CoV-2. Thus, Nagaradi Kashayam, a classical formulation can be a trial candidate for conducting further clinical trial.
